ZNF281: A Potential Drug Target and Biomarker for Parkinson's Disease
ZNF281: A Potential Drug Target and Biomarker for Parkinson's Disease
Parkinson's disease is a neurodegenerative disorder characterized by the progressive loss of dopamine-producing neurons in the brain. It is a common cause of movement disorders, including tremors and stiffness. Although there is currently no cure for Parkinson's disease, treatments such as drugs that can slow the progression of the disease and alleviate its symptoms are available. One potential drug target for Parkinson's disease is ZNF281, a zinc finger protein that has been identified as a potential biomarker and drug target for the disease.
ZNF281 is a protein that is expressed in various tissues throughout the body, including the brain. It is composed of four domains: a N-terminal zinc finger, a unique central domain, a C-terminal domain, and a variable N-terminal domain . The N-terminal domain is the most well-studied, and it contains a zinc finger that is involved in the regulation of gene expression. The C-terminal domain is known for its role in protein-protein interactions and is involved in the regulation of cellular processes such as cell adhesion and migration.
Recent studies have suggested that ZNF281 may be a potential drug target for Parkinson's disease. One study published in the journal Nature Medicine used ZNF281 as a potential drug target because it was shown to be overexpressed in the brains of people with Parkinson's disease. The study found that ZNF281 was overexpressed in the basal ganglia, which is the part of the brain that is affected in Parkinson's disease. The study suggests that overexpression of ZNF281 in the basal ganglia may contribute to the development and progression of Parkinson's disease.
Another study published in the journal Parkinson's Disease found that inhibiting the activity of ZNF281 using small molecule inhibitors improved motor function in rats with Parkinson's disease. The study suggests that inhibiting the activity of ZNF281 may be a potential strategy for treating Parkinson's disease.
In addition to its potential as a drug target, ZNF281 has also been identified as a potential biomarker for Parkinson's disease. One study published in the journal Neurochemist used ZNF281 as a potential biomarker for Parkinson's disease because it was shown to be decreased in the brains of people with Parkinson's disease. The study found that ZNF281 levels were decreased in the basal ganglia, which is the part of the brain that is affected in Parkinson's disease. The study suggests that decreased levels of ZNF281 in the basal ganglia may be a potential biomarker for Parkinson's disease.
Another study published in the journal Parkinson's Disease found that ZNF281 was decreased in the brains of people with Parkinson's disease, and the levels of ZNF281 were correlated with the severity of Parkinson's disease. The study suggests that decreased levels of ZNF281 in the brains of people with Parkinson's disease may be a potential biomarker for the disease.
In conclusion, ZNF281 is a protein that has been identified as a potential drug target and biomarker for Parkinson's disease. Its involvement in the regulation of gene expression and its potential as a drug target makes it an attractive target for researchers and pharmaceutical companies. Further studies are needed to determine the role of ZNF281 in Parkinson's disease and its potential as a drug.
Protein Name: Zinc Finger Protein 281
Functions: Transcription repressor that plays a role in regulation of embryonic stem cells (ESCs) differentiation. Required for ESCs differentiation and acts by mediating autorepression of NANOG in ESCs: binds to the NANOG promoter and promotes association of NANOG protein to its own promoter and recruits the NuRD complex, which deacetylates histones. Not required for establishement and maintenance of ESCs (By similarity). Represses the transcription of a number of genes including GAST, ODC1 and VIM. Binds to the G-rich box in the enhancer region of these genes
The "ZNF281 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF281 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ZNF282 | ZNF283 | ZNF284 | ZNF285 | ZNF285CP | ZNF286A | ZNF286B | ZNF287 | ZNF292 | ZNF295-AS1 | ZNF296 | ZNF3 | ZNF30 | ZNF300 | ZNF300P1 | ZNF302 | ZNF304 | ZNF311 | ZNF316 | ZNF317 | ZNF318 | ZNF319 | ZNF32 | ZNF32-AS1 | ZNF32-AS2 | ZNF32-AS3 | ZNF320 | ZNF321P | ZNF322 | ZNF322P1 | ZNF324 | ZNF324B | ZNF326 | ZNF329 | ZNF330 | ZNF331 | ZNF333 | ZNF334 | ZNF335 | ZNF337 | ZNF33A | ZNF33B | ZNF33BP1 | ZNF34 | ZNF341 | ZNF341-AS1 | ZNF343 | ZNF345 | ZNF346 | ZNF347 | ZNF35 | ZNF350 | ZNF350-AS1 | ZNF354A | ZNF354B | ZNF354C | ZNF355P | ZNF358 | ZNF362 | ZNF365 | ZNF366 | ZNF367 | ZNF37A | ZNF37BP | ZNF382 | ZNF383 | ZNF384 | ZNF385A | ZNF385B | ZNF385C | ZNF385D | ZNF385D-AS1 | ZNF385D-AS2 | ZNF391 | ZNF394 | ZNF395 | ZNF396 | ZNF397 | ZNF398 | ZNF402P | ZNF404 | ZNF407 | ZNF407-AS1 | ZNF408 | ZNF41 | ZNF410 | ZNF414 | ZNF415 | ZNF416 | ZNF417 | ZNF418 | ZNF419 | ZNF420 | ZNF423 | ZNF425 | ZNF426 | ZNF428 | ZNF429 | ZNF43 | ZNF430
